Recently, the term monoclonal gammopathy of renal significance (MGRS) was introduced to distinguish monoclonal gammopathies that result in the development of kidney disease from those that are benign. By definition, patients with MGRS have B cell clones that do not meet the definition of multiple myeloma or lymphoma. Nevertheless, these clones produce monoclonal proteins that are capable of injuring the kidney resulting in permanent damage. 
Introduction
Monoclonal gammopathy of renal significance (MGRS) is defined by the causal relationship between a small B cell clone and renal disease, usually through deposition of the secreted monoclonal immunoglobulin (MIg), or a fragment thereof. 1 The spectrum of MGRS is evolving, with the recent description of novel entities. With the exception of immunoglobulin light chain (AL) amyloidosis, few studies have focused on therapeutic issues. The International Kidney and Monoclonal Gammopathy Research Group (IKMG) initiated a collaborative effort aimed at delineating treatment strategies.
What is MGRS?
The B cell clone corresponds to the definition of a "dangerous small B cell clone", suggesting that its deleterious consequences are not directly related to cellular proliferation but to other mechanisms, such as MIg deposition. Non-amyloid fibrillary glomerulonephritis
should not be considered as MGRS because it is nearly always characterized by polyclonal IgG deposits without a detectable clonal B cell disorder. 5, 6 In MGRS, deposits of different ultrastructural patterns derived from the same MIg can occur. For instance, fibrillar AL and amorphous Randall-type deposits can coexist in the same patient. 7 In most cases, the overall
For personal use only. on April 19, 2017 . by guest www.bloodjournal.org From survival of patients with MGRS is significantly better than that of multiple myeloma, but the renal outcomes are not. 1 The exception is patients with AL amyloidosis particularly those with cardiac involvement where death can occur rapidly. 8 Many patients who develop end stage renal disease (ESRD)are often not considered for kidney transplantation due to their high rates of recurrence.
In a patient in whom MGRS is suspected, it is essential to assess i) the characteristics of monoclonal gammopathy, particularly its isotype and whether it corresponds to an overt lymphoid and/or plasmacytic disorder and ii) the type of nephropathy and its impact on renal function. In addition, it is mandatory to carefully search for extra-renal manifestations. To accurately characterize the renal disease, a kidney biopsy with detailed immunofluorescence (IF) and electron microscopic (EM) studies to identify deposit composition and pattern of organization is needed in most cases. The one exception is AL amyloidosis which can be diagnosed if AL deposits can be demonstrated in other tissues such as fat.
Which therapeutic options?

Treatment of the B cell clone
To date, no strategy is available to inhibit MIg tissue deposition, or to directly clear the already deposited material. Innovative strategies that are currently in early clinical testing include small molecule weight inhibitors of serum amyloid P protein (SAP) and monoclonal antibody against neoepitope on immunoglobulin light chains. 9 Thus, targeting the underlying B cell clone with chemotherapy, although it is not an evidently malignant clone per se, is the only available therapeutic option for MGRS.
The choice of chemotherapeutic agents should take into account their renal metabolism and potential renal and extra-renal toxicity. For alkylating agents, cyclophosphamide is preferred to melphalan due to its lower toxicity in patients with reduced
For personal use only. on April 19, 2017 . by guest www.bloodjournal.org From kidney function. 10 Similarly, within the immunomodulatory drug class (IMiD), thalidomide may be more appropriate than lenalidomide since the latter is in part cleared renally and may also sometimes worsen renal function in certain disease states notably in AL amyloidosis. 11, 12 In contrast, bortezomib can be used without dose adjustment with a good tolerance profile, including in the setting of end-stage renal disease (ESRD).
13-15
The risk of peripheral neuropathy remains a concern, but has been shown to be reduced by weekly administration and the use of the sub-cutaneous route of administration in patients with myeloma. 16 Bendamustine, which has been proposed for the treatment of various lymphoid disorders, has also a predominantly non-renal metabolism and can be given to patients with ESRD. 17, 18 Among nucleoside analogs, fludarabine requires dose adaptation and should be avoided in patients with renal failure. 19 The use of rituximab and other anti-CD20 monoclonal antibodies raises no concerns in patients with renal impairment, including ESRD.
20,21
High dose melphalan (HDM) supported by autologous peripheral blood stem cell transplantation (ASCT) may be a therapeutic option in some patients. It is essential to collect stem cells early in the course of the treatment, avoiding excessive prior use of drugs with potential stem cell damage, such as melphalan and lenalidomide. HDM/ASCT is feasible in MM patients with renal failure, even requiring dialysis. [22] [23] [24] However, mortality and morbidity, including the risk of worsening renal function, increases with the severity of renal impairment. [25] [26] [27] Melphalan dose should be adjusted in patients with chronic kidney disease (CKD) stage 3 or above and risk/benefit ratio should be carefully evaluated in each case.
The underlying plasma cell clone responsible for MGRS may manifest as a solitary plasmacytoma. Although this situation is rare, it has key therapeutic implications. Local radiotherapy may result in a complete and sustained control of the MIg production and, consequently, of its renal consequences. 28 The initial work-up of MGRS should include a
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In MGRS, assessment of hematological response is crucial. It depends upon the evaluation of the MIg component that is responsible for renal lesions. In AL amyloidosis, measurement of serum free light chain (FLC) provides an essential tool. Current response criteria in AL amyloidosis distinguishes complete response (normal FLC ratio and negative serum and urine immunofixation), very good partial response (difference between involved and uninvolved FLCs [dFLC] < 40 mg/L), partial response (dFLC decrease > 50%), and no response. 29 The use of the same criteria in all types of MGRS due to the deposition of monoclonal light chain (LC), particularly LCDD and Fanconi syndrome is logical. In MGRS involving an intact MIg, the criteria recommended in MM should be applied. 30 When the causal MIg is not detectable or difficult to measure, evaluating the cellular response, usually by repeated bone marrow examination, is the only way to assess the hematological efficacy of treatment. In all cases, renal (and extra-renal, if present) response should be regularly monitored, bearing in mind that it is usually delayed and depends on the quality of the hematological response. 31 Whether new molecular or cytometric techniques are useful to detect residual disease and impact outcomes deserves further investigation.
32
In all MGRS subtypes, evidence for relapse of the underlying clonal disease should prompt the clinician to reinitiate therapy, based on criteria similar to the ones applied for the initiation of primary therapy. Treatment choice should take into account characteristics of the first response, toxicity of prior therapies, general status and renal function.
Treatment of renal disease
MGRS should be monitored according to usual best practices including, for example, thrombotic and infectious risk prevention in case of nephrotic syndrome. Except in AL As MIDD is rare, controlled studies are lacking and the therapeutic approach is based on consensus opinion. Achieving the best hematological response appears to be as important as in AL. It may result in regression of MIg tissue deposits, providing that complete and sustained remission has been obtained. 64, 65 Small retrospective series suggested that HDM/ASCT is a good therapeutic option, with high hematological response rates and low treatment related mortality (TRM). This contrasts with AL amyloidosis in which patients are much more fragile with frequent systemic complications that increase TRM.
64-71
Data regarding HDM/ASCT have been published before the era of novel anti-myeloma agents. Preliminary results suggest that bortezomibbased regimens could produce hematological response rates similar to those obtained with HDM/ASCT, as is the case in MM.
72-77
Taking into account these points, therapeutic recommendations should be based on the degree of renal impairment:
-In patients with CKD stages 1-3, the main goal of treatment is preserving kidney function. The panel recommends the use of a bortezomib-based regimen, such as CBD, as front line. HDM/ASCT should then be considered in selected patients with good performance status and no significant extra-renal manifestations, particularly when they have achieved only partial hematological response to the initial treatment.
-In patients with CKD stages 4 and 5, the probability of renal recovery is low. In patients not eligible for renal transplantation, the main goal of the treatment is -In patients with few systemic symptoms and a low-grade underlying B-cell proliferation, observation alone is recommended, including serial assessment of renal parameters, since renal manifestations may occur secondarily.
-In patients with symptomatic and/or progressive systemic disease, particularly in the presence of renal complications, therapy is indicated and should be selected based on the underlying clone:
• If it is plasmacytic, usually secreting a monoclonal IgG (or IgA), treatment should rely on anti-myeloma agents. In patients with renal failure, bortezomib, cyclophosphamide and/or thalidomide-based regimens should be used. Rituximab is not indicated. In selected patients, HDM/ASCT may be considered.
• If it is lympho-plasmacytic, usually associated with a monoclonal IgM, the treatment should be that of WM, currently based on Rituximab-containing regimens.
• If the underlying disease is chronic lymphocytic leukemia (CLL) or a B-cell lymphoma of any type, the treatment should be adapted accordingly.
In all cases, bendamustine, which is not eliminated by the kidney, is likely to be a good alternative. In patients with acute severe systemic symptoms, complete plasma exchange is indicated in addition to chemotherapy. 
90
-In all patients with overt WM or B-cell lymphoma, chemotherapy should be considered in patients with symptoms more significant than occasional purpura regardless of their HCV status. The regimen should be defined taking into account the type of the underlying B-cell clone and the level of renal function (see above).
91
Immunotactoid glomerulopathy (ITG)
ITG, also referred to as glomerulonephritis with organized microtubular monoclonal Ig deposits (GOMMID) is a rare glomerular disease with proteinuria, frequent nephrotic syndrome, hematuria, CKD and hypertension. Extra-renal manifestations are uncommon.
Glomerular lesions are usually characterized by atypical membranous and MPGN patterns.
By IF, glomerular deposits are composed of monotypic IgG and complement components. EM, which is required for the diagnosis, shows a typical organization of deposits into microtubules of 10 to 60 nm in diameter, arranged in parallel bundles. 3, 5, 6, 92 Similar microtubular inclusions may be observed in the cytoplasm of the circulating and medullary clonal B-cell population. 3, 5 Importantly, the underlying B-cell lymphoid disorder is a CLL or a small lymphocytic lymphoma in more than half of the cases. A low-grade plasma cell clone is less frequent.
5,92
Accordingly, the initial workup should include a careful search for a clonal B-cell population among peripheral blood and bone marrow lymphocytes, including phenotypic and Ig gene rearrangement studies. Although therapeutic choice relies upon few small case series, a CLL-adapted treatment may be proposed in most patients. In case of severe CKD, cyclophosphamide and/or bendamustine-based regimens including corticosteroids may be recommended. The addition of rituximab should be considered in patients with overt CLL. In patients with gammopathy only, the role of rituximab is questionable and bortezomib-based therapy may be considered.
Proliferative glomerulonephritis with monoclonal Ig deposits (PGNMID) PGNMID is a recently described entity that should be distinguished from Randall-type MIDD. Both diseases are featured by glomerular non-organized MIg deposits. However, in PGNMID, deposits usually consist of an entire MIg (most commonly IgG3κ), with a granular non-linear appearance by IF and EM, without detectable deposits along tubular basement membranes and around vascular myocytes. Various patterns can be observed, including mesangial, atypical membranous and membranoproliferative GN. Globally, PGNMID resembles an immune complex-like GN, but with monotypic Ig deposits, a feature that should draw the pathologist's attention. [93] [94] [95] [96] Extra-renal manifestations are rare and PGNMID appears as a renal limited disorder, with prominent glomerular symptoms and frequent CKD. Importantly, sensitive techniques including nephelometric tests for FLCs can detect a serum and urine MIg in approximately one third of patients only. A monoclonal proliferation of plasma cells in the bone marrow is found in less than 10% of patients. [93] [94] [95] [96] Some authors are reluctant to recommend chemotherapy in PGNMID with no detectable MIg. However, monotypic glomerular deposits are the result of a circulating MIg, which indicates the presence of an underlying B-cell disorder. Consequently, PGNMID almost always recurs after renal transplantation.
37,97
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The panel recommends adapting the therapeutic approach to the severity of renal disease:
-In patients with CKD stages 1-2, proteinuria of less than 1g/day and no evidence of progressive disease, symptomatic measures only may be advised with careful surveillance. In such cases, occasional spontaneous renal remissions may occur.
-In patients with CKD stages 1-2 and high-grade proteinuria (over 1g/day) or progressive disease, and in patients with CKD stages 3-4, chemotherapy is indicated. Cyclophosphamide and bortezomib are the drugs of choice, and a CBDlike regimen is a good option. In some patients aged less than 65 years, HDM/ASCT may be performed. Preliminary reports suggest a beneficial effect of rituximab, including in patients without a detectable B-cell clone. 90 However, it seems reasonable proposing rituximab only to patients in whom an associated CD-20 positive B-cell clone can be demonstrated.
-In patients with CKD stage 5 who are candidates for renal transplantation, the achievement of a complete hematological remission is a key goal for patients with a detectable monoclonal gammopathy. 37, 97 Thus, HDM/ ASCT should be strongly considered. For those who never had a detectable monoclonal gammopathy or plasma cell clone, there is no consensus regarding their treatment prior to kidney transplant. In contrast, in patients ineligible for renal transplantation, the benefit of chemotherapy is highly questionable and conservative treatment should be recommended.
Acquired Fanconi syndrome (FS)
Acquired FS is characterized by proximal tubular dysfunction secondary to accumulation of monoclonal κ LCs crystalline inclusions within the endolysosomal Very few series of LC-associated FS have been published and the efficacy of the socalled novel anti-myeloma agents has not been evaluated. In most cases, FS appears to slowly progress toward ESRD and rarely symptomatic myeloma. 33,98 Accordingly, therapeutic decisions should take into account treatment side effects, particularly the potential risk of secondary myelodysplastic syndrome from alkylating agents.
98
Symptomatic measures to prevent osteomalacia are mandatory. All patients with an associated overt lymphoid disorder should receive appropriate chemotherapy. For the rare patients with symptomatic CSH, steroids should be considered in addition to chemotherapy.
Otherwise, treatment choices should be adapted to the degree of renal failure:
• In patients with CKD stages1-3, chemotherapy should be considered to try to slow progression to ESRD. Cyclophosphamide, Bendamustine may also be utilized. HDM/ASCT may be performed in selected non-responding patients, although the benefit of this strategy remains to be proven.
In patients with CKD stages 4-5 who are eligible for renal allograft, chemotherapy, including HDM/ASCT should be considered either prior and/or after transplantation. In patients who will not be candidate for renal transplantation, there is no benefit to introduce chemotherapy.
Miscellaneous
In addition to kidney deposition of a MIg, other mechanisms may induce renal lesions in MGRS. They may involve the secretion of various biological factors and/or autoantibody activity of the MIg.
The so-called POEMS syndrome can include renal manifestations, usually featured by vascular and glomerular thrombotic microangiopathy including mesangiolysis. These are considered to be due to the secretion of vascular endothelial growth factor by the clonal cells or their environment, which is a hallmark of this syndrome. Whether the causal plasmacytic proliferation is localized or not is the key point for therapeutic decisions. regulatory protein is the main current hypothesis. Since the disease course is rapid, with a high risk of recurrence after renal transplantation, chemotherapy should be given early.
104,105
Conclusion
Current treatment of MGRS is based on therapies targeting the causal B-cell clone with treatment choices based on extrapolation of treatments used for the equivalent overt malignancy. Therapeutic choices should take into account the renal characteristics of the disease, particularly the risk of CKD progression, the presence and severity of extra-renal manifestations and the safety profile of anti-neoplastic drugs in renal impairment. Early diagnosis, when renal function is still preserved, usually facilitates treatment management and results in better long-term outcome. Since MGRS is a heterogeneous and relatively rare entity, a common effort of both nephrologists and hematologists inside well-designed prospective collaborative studies is required to improve management.
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